In this work, we emulated a target clinical trial comparing rate of acute healthcare utilization, all-cause mortality, composite cardiovascular events, and kidney disease progression in patients with moderate to advanced CKD initiating GLP1-RAs versus DPP4is in real world practice within the Veterans Healthcare Administration (VHA). Here, GCG is linked to kidney disorder.